Global Selective Cox-2 Inhibitors Market Growth (Status and Outlook) 2025-2031

According to this study, the global Selective Cox-2 Inhibitors market size will reach US$ million by 2031.

United States market for Selective Cox-2 Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Selective Cox-2 Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Selective Cox-2 Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Selective Cox-2 Inhibitors players cover Boehringer-Ingelheim, TerSera Therapeutics, Iroko Pharmaceuticals, Apotex, Yung Shin Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Selective Cox-2 Inhibitors Industry Forecast” looks at past sales and reviews total world Selective Cox-2 Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected Selective Cox-2 Inhibitors sales for 2025 through 2031. With Selective Cox-2 Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Selective Cox-2 Inhibitors industry.

This Insight Report provides a comprehensive analysis of the global Selective Cox-2 Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Selective Cox-2 Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Selective Cox-2 Inhibitors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Selective Cox-2 Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Selective Cox-2 Inhibitors.

This report presents a comprehensive overview, market shares, and growth opportunities of Selective Cox-2 Inhibitors market by product type, application, key players and key regions and countries.

Segmentation by Type:
Meloxicam
Celecoxib
Etoricoxib
Imrecoxib
Etodolac
Parecoxib
Others

Segmentation by Application:
Rheumatoid Arthritis
Osteoarthritis
Spondylosis Chronica Ankylopoietica
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Boehringer-Ingelheim
TerSera Therapeutics
Iroko Pharmaceuticals
Apotex
Yung Shin Pharmaceutical
Breckenridge Pharmaceutical
Meda Pharmaceuticals
Cipla
Glenmark Pharmaceuticals
Teva
PuraCap Pharmaceutical
Almirall Limited
Lupin Pharmaceuticals
Aurobindo Pharma
Pfizer
Mylan
Takeda
Bayer
Novacap
Abbott
Geri-Care
Perrigo
Kopran
Merck
Hengrui pharmaceutical
Kelun Group
Qilu Pharmaceutical
Taro Pharmaceuticals 

Please note: The report will take approximately 2 business days to prepare and deliver. Show more